Literature DB >> 11395138

Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.

J E Thommesen1, T E Michaelsen, G Å Løset, I Sandlie, O H Brekke.   

Abstract

The classical complement activation cascade of the immune system is initiated by multivalent binding of its first component, C1q, to the Fc region of immunoglobulins in immune complexes. The C1q binding site on mouse IgG2b has been shown to contain the amino acids Glu 318, Lys 320 and Lys 322 in the C(H)2 domain (Duncan, A.R., Winter, G.,1988. The binding site for C1q on IgG. Nature 322 738-740). Identical or closely related motifs are found on all IgGs in all species, and the binding site has therefore been thought to be universal. However, the results from another study indicate that the site is different in human IgG1 molecules (Morgan, A., Jones, N.D., Nesbitt, A.M., et al., 1995. The N-terminal end of the C(H)2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology 86 319-324). To determine the site(s) responsible for complement activation in anti-NIP-mouse/human IgG3 antibodies, we have mutated amino acids Lys 276, Tyr 278, Asp 280, Glu 318, Lys 320 and Lys 322 in two beta-strands in the C(H)2 domains of human IgG3. In addition, we mutated the Glu 333, which resides in close proximity to the postulated C1q-binding site of mouse IgG2b, as well as Leu 235 in the lower hinge region. All mutants were tested in Antibody Dependent Complement Mediated Lysis (ADCML)(4) assays, where the antigen concentration on target cells was varied and human serum was complement source. Only the mutants that lacked the positively charged side chain of lysine in position 322 showed strong reduction in ADCML, particularly at low antigen density on target cells. Alanine scanning of positions 318 and 320 did not affect ADCML, contrary to what was observed for mouse IgG2b. Neither did a leucine to glutamic acid mutation in position 235 have the effect that has been reported for human IgG1. These results suggest that the complement binding site on human IgG3 molecules is different from that found on mouse IgG2b, and possibly on human IgG1 as well. Thus the contact site may not be conserved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11395138     DOI: 10.1016/s0161-5890(01)00010-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  26 in total

1.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

2.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

3.  IgG2m4, an engineered antibody isotype with reduced Fc function.

Authors:  Zhiqiang An; Gail Forrest; Renee Moore; Michael Cukan; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jing Zhang Zhao; Ping Lu; Jin Hua; Christopher R Gibson; Barrett R Harvey; Donna Montgomery; Dennis Zaller; Fubao Wang; William Strohl
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 4.  Anti-GD2 antibody therapy for GD2-expressing tumors.

Authors:  Fariba Navid; Victor M Santana; Raymond C Barfield
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

5.  The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.

Authors:  Lucy E Rayner; Gar Kay Hui; Jayesh Gor; Richard K Heenan; Paul A Dalby; Stephen J Perkins
Journal:  J Biol Chem       Date:  2015-02-06       Impact factor: 5.157

Review 6.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

7.  Structural characterization of the Man5 glycoform of human IgG3 Fc.

Authors:  Ishan S Shah; Scott Lovell; Nurjahan Mehzabeen; Kevin P Battaile; Thomas J Tolbert
Journal:  Mol Immunol       Date:  2017-10-12       Impact factor: 4.407

8.  Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.

Authors:  Doralina L Anghelescu; Jacob L Goldberg; Lane G Faughnan; Jianrong Wu; Shenghua Mao; Wayne L Furman; Victor M Santana; Fariba Navid
Journal:  Pediatr Blood Cancer       Date:  2014-11-08       Impact factor: 3.167

9.  Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Authors:  Kham R Trinh; Alex Vasuthasawat; Kristopher K Steward; Reiko E Yamada; John M Timmerman; Sherie L Morrison
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

10.  Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.

Authors:  Stephen A Beers; Claude H T Chan; Sonya James; Ruth R French; Kathrine E Attfield; Claire M Brennan; Anupama Ahuja; Mark J Shlomchik; Mark S Cragg; Martin J Glennie
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.